PyL (18F-DCFPyl)

December 30, 2019January 9, 2020

PyL Imaging Agent Accurately Detects Recurrent Prostate Cancer Lesions, Trial Shows

News

Progenics Pharmaceuticals’ PyL, a new imaging agent for positron emission tomography (PET) scans, can accurately detect the location of recurrent prostate cancer lesions, according to data from a Phase 3 clinical trial. “The ... Read more

July 25, 2019

PyL Imaging Agent Ably Detects Lesions Outside the Prostate, Phase 2/3 Trial Shows

News

PyL, a new imaging agent for positron emission topography (PET) scans, can accurately detect prostate cancer lesions outside the prostate, whether in nearby lymph nodes or in distant locations, clinical ... Read more

December 12, 2018

Phase 3 Trial Testing New Imaging Agent for Prostate Cancer Detection Doses First Patient

News

A Phase 3 trial evaluating Progenics Pharmaceuticals‘ new imaging agent to help detect prostate cancer recurrence has begun dosing participants. The agent, called PyL (18F-DCFPyl), is a tracing substance composed of the prostate ... Read more